Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

• Status: Completed
• Trial end date: 2012-09-07
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability and effectiveness of DS-5565 compared to placebo (inactive substance) and pregabalin in diabetic subjects with DPN.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Inc.; Daiichi Sankyo, Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

1. Age > 18 years of age

2. Able to give informed consent and willing to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures

3. Type 1 or type 2 diabetes with a hemoglobin A1c (HbA1c) ≤ 10% at Screening and on a stable antidiabetic medication regimen for at least 30 days prior to Screening (insulin therapy is acceptable)

4. Painful distal symmetrical sensorimotor polyneuropathy (as per American Society of Pain Educators guidelines ) diagnosed for at least 6 months, based on neurological history and/or examination; diagnosis includes absent or reduced deep tendon reflexes at both ankles

5. At Screening, a pain score of ≥ 40 mm on the SF-MPQ VAS

6. At Randomization, a pain score of ≥ 40 mm on the SF-MPQ VAS and an ADPS of ≥ 4 on the 11-point NRS, the latter calculated from a minimum of 4 pain ratings in daily diaries obtained during the 1-week Baseline Period (prior to randomization)

7. Creatinine clearance > 60 mL/min (estimated using the Cockcroft-Gault equation)

8. Antidiabetic and other medications anticipated to remain stable and constant during the study period

9. Women of child bearing potential (WOCBP) must be using an adequate method of contraception as detailed in the protocol to avoid pregnancy during the study and for 4 weeks after study completion

Exclusion Criteria:

1. Diagnosis of mononeuropathy

2. Use of concomitant medications that may confound assessments of efficacy and/or safety (see Section 5.2)

3. Major psychiatric disorders

4. Have had a malignancy other than basal cell carcinoma within the past 2 years

5. At Visit 1, have a white blood cell count < 2500/mm3, neutrophil count < 1500/mm3, or platelet count < 100 x 103/mm3

6. Clinically significant unstable diabetes mellitus, unstable hepatic, respiratory, or hematologic illness, unstable cardiovascular disease (including myocardial infarction in the 3 months prior to Visit 1), or symptomatic peripheral vascular disease

7. Clinically significant findings on the Screening ECG

8. History of pernicious anemia, untreated hypothyroidism, chronic hepatitis B, hepatitis B within the past 3 months, or human immunodeficiency virus infection

9. Amputations of body parts other than toes

10. Prior therapeutic failure of pregabalin or gabapentin (considered unresponsive or intolerant to treatment); therapeutic failure implies lack of efficacy following full titration to effective doses (eg, 300 mg/day for pregabalin)

11. Known hypersensitivity to pregabalin or gabapentin

12. Requirement for concomitant anticonvulsant and antidepressant therapy, with the exception of stable doses of SSRIs

13. Neurologic disorders unrelated to DPN that may confound the assessment of pain associated with DPN

14. Skin conditions that could alter sensation

15. Other sources of pain that may confound assessment or self-evaluation of the pain due to DPN

16. Abuse of prescription medications, street drugs or alcohol (including alcohol dependence) within the last 1 year

17. Current enrollment in another investigational study, participation in another investigational study with the past 30 days, or other current or recent use of any investigational drug

18. Pregnancy (as based on lab test results) or breast feeding

19. Laboratory values exceeding limits listed in Table 4.1 of the protocol